Abstract
Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.
Keywords: Acetylcholine, acetylcholinesterase inhibitors, Alzheimer disease, cholinergic pathways, MCI, mild cognitive impairment, RBD, REM behavior disorder, REM, rivastigmine (RVT), sleep.
Current Alzheimer Research
Title:Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Volume: 11 Issue: 3
Author(s): Valerio Brunetti, Anna Losurdo, Elisa Testani, Leonardo Lapenta, Paolo Mariotti, Camillo Marra, Paolo Maria Rossini and Giacomo Della Marca
Affiliation:
Keywords: Acetylcholine, acetylcholinesterase inhibitors, Alzheimer disease, cholinergic pathways, MCI, mild cognitive impairment, RBD, REM behavior disorder, REM, rivastigmine (RVT), sleep.
Abstract: Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.
Export Options
About this article
Cite this article as:
Brunetti Valerio, Losurdo Anna, Testani Elisa, Lapenta Leonardo, Mariotti Paolo, Marra Camillo, Rossini Maria Paolo and Marca Della Giacomo, Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment, Current Alzheimer Research 2014; 11 (3) . https://dx.doi.org/10.2174/1567205011666140302195648
DOI https://dx.doi.org/10.2174/1567205011666140302195648 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection by the α2-Adrenoceptor Agonist, Dexmedetomidine, in Experimental Stroke Models
Vascular Disease Prevention (Discontinued) Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond
Current Drug Metabolism Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Potential Therapeutic Targets in Cirrhotic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Acellular Spinal Cord Scaffold Implantation Promotes Vascular Remodeling with Sustained Delivery of VEGF in a Rat Spinal Cord Hemisection Model
Current Neurovascular Research Fatty Acid Amide Hydrolase: A Potential Target for Next Generation Therapeutics
Current Pharmaceutical Design Anti - TNF Therapy for Crohns Disease
Current Pharmaceutical Design Review of Medicinal Plants Common to Traditional Chinese and Indian Medicines with Relevance to Non-Communicable Diseases
Current Traditional Medicine Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Nocturia in Obstructive Sleep Apnea-Hypopnea Syndrome: An Underappreciated Symptom
Current Respiratory Medicine Reviews Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology <i>Scaphechinus mirabilis</i> Extract Effectively Inhibits the Proliferation of BPH-1 and LNCaP Prostate Epithelial Cells
The Natural Products Journal Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry A Possible Placental Factor for Preeclampsia: sFlt-1
Current Medicinal Chemistry The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy
Current Topics in Medicinal Chemistry Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease
Current Neuropharmacology